Summary

Gastroparesis Treatment Market – Scope of Report
TMR’s report on the global gastroparesis treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global gastroparesis treatment market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global gastroparesis treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the gastroparesis treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global gastroparesis treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global gastroparesis treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global gastroparesis treatment market.

The report delves into the competitive landscape of the global gastroparesis treatment market. Key players operating in the global gastroparesis treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global gastroparesis treatment market profiled in this report.

Key Questions Answered in Global gastroparesis treatment Market Report
• What is the sales/revenue generated by gastroparesis treatment across all regions during the forecast period?
• What are the opportunities in the global gastroparesis treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Gastroparesis Treatment Market – Research Objectives and Research Approach
The comprehensive report on the global gastroparesis treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global gastroparesis treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global gastroparesis treatment market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Gastroparesis Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gastroparesis Treatment Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Gastroparesis Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
6.3.1. Prokinetic Agents
6.3.2. Antiemetic Drugs
6.3.3. Proton Pump Inhibitors
6.3.4. Others (Botulinum Toxin Injections, etc.)
6.4. Market Attractiveness, by Drug Class
7. Global Gastroparesis Treatment Market Analysis and Forecast, by Disease Indication
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Indication, 2020-2034
7.3.1. Diabetes Gastroparesis
7.3.2. Idiopathic Gastroparesis
7.3.3. Post-surgical Gastroparesis
7.4. Market Attractiveness, by Disease Indication
8. Global Gastroparesis Treatment Market Analysis and Forecast, By Type
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, By Type, 2020-2034
8.3.1. Over-the-Counter Drugs
8.3.2. Prescription Drugs
8.4. Market Attractiveness, By Type
9. Global Gastroparesis Treatment Market Analysis and Forecast, by Route of Administration
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Route of Administration, 2020-2034
9.3.1. Oral
9.3.2. Injectables
9.3.3. Nasal
9.4. Market Attractiveness, by Route of Administration
10. Global Gastroparesis Treatment Market Analysis and Forecast, by Distribution Channel
10.1. Introduction and Definitions
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Distribution Channel, 2020-2034
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Attractiveness, by Distribution Channel
11. Global Gastroparesis Treatment Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2020-2034
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness, by Region
12. North America Gastroparesis Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2020-2034
12.2.1. Prokinetic Agents
12.2.2. Antiemetic Drugs
12.2.3. Proton Pump Inhibitors
12.2.4. Others (Botulinum Toxin Injections, etc.)
12.3. Market Attractiveness, by Drug Class
12.4. Market Value Forecast, by Disease Indication, 2020-2034
12.4.1. Diabetes Gastroparesis
12.4.2. Idiopathic Gastroparesis
12.4.3. Post-surgical Gastroparesis
12.5. Market Attractiveness, by Disease Indication
12.6. Market Value Forecast, By Type, 2020-2034
12.6.1. Over-the-Counter Drugs
12.6.2. Prescription Drugs
12.7. Market Attractiveness, By Type
12.8. Market Value Forecast, by Route of Administration, 2020-2034
12.8.1. Oral
12.8.2. Injectables
12.8.3. Nasal
12.9. Market Attractiveness, by Route of Administration
12.10. Market Value Forecast, by Distribution Channel, 2020-2034
12.10.1. Hospital Pharmacies
12.10.2. Retail Pharmacies
12.10.3. Online Pharmacies
12.11. Market Attractiveness, by Distribution Channel
12.12. Market Value Forecast, by Country/Sub-region, 2020-2034
12.12.1. U.S.
12.12.2. Canada
12.13. Market Attractiveness Analysis
12.13.1. By Drug Class
12.13.2. By Disease Indication
12.13.3. By Type
12.13.4. By Route of Administration
12.13.5. By Distribution Channel
12.13.6. By Country
13. Europe Gastroparesis Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2020-2034
13.2.1. Prokinetic Agents
13.2.2. Antiemetic Drugs
13.2.3. Proton Pump Inhibitors
13.2.4. Others (Botulinum Toxin Injections, etc.)
13.3. Market Attractiveness, by Drug Class
13.4. Market Value Forecast, by Disease Indication, 2020-2034
13.4.1. Diabetes Gastroparesis
13.4.2. Idiopathic Gastroparesis
13.4.3. Post-surgical Gastroparesis
13.5. Market Attractiveness, by Disease Indication
13.6. Market Value Forecast, By Type, 2020-2034
13.6.1. Over-the-Counter Drugs
13.6.2. Prescription Drugs
13.7. Market Attractiveness, By Type
13.8. Market Value Forecast, by Route of Administration, 2020-2034
13.8.1. Oral
13.8.2. Injectables
13.8.3. Nasal
13.9. Market Attractiveness, by Route of Administration
13.10. Market Value Forecast, by Distribution Channel, 2020-2034
13.10.1. Hospital Pharmacies
13.10.2. Retail Pharmacies
13.10.3. Online Pharmacies
13.11. Market Attractiveness, by Distribution Channel
13.12. Market Value Forecast, by Country/Sub-region, 2020-2034
13.12.1. Germany
13.12.2. U.K.
13.12.3. France
13.12.4. Italy
13.12.5. Spain
13.12.6. Rest of Europe
13.13. Market Attractiveness Analysis
13.13.1. By Drug Class
13.13.2. By Disease Indication
13.13.3. By Type
13.13.4. By Route of Administration
13.13.5. By Distribution Channel
13.13.6. By Country/Sub-region
14. Asia Pacific Gastroparesis Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2020-2034
14.2.1. Prokinetic Agents
14.2.2. Antiemetic Drugs
14.2.3. Proton Pump Inhibitors
14.2.4. Others (Botulinum Toxin Injections, etc.)
14.3. Market Attractiveness, by Drug Class
14.4. Market Value Forecast, by Disease Indication, 2020-2034
14.4.1. Diabetes Gastroparesis
14.4.2. Idiopathic Gastroparesis
14.4.3. Post-surgical Gastroparesis
14.5. Market Attractiveness, by Disease Indication
14.6. Market Value Forecast, By Type, 2020-2034
14.6.1. Over-the-Counter Drugs
14.6.2. Prescription Drugs
14.7. Market Attractiveness, By Type
14.8. Market Value Forecast, by Route of Administration, 2020-2034
14.8.1. Oral
14.8.2. Injectables
14.8.3. Nasal
14.9. Market Attractiveness, by Route of Administration
14.10. Market Value Forecast, by Distribution Channel, 2020-2034
14.10.1. Hospital Pharmacies
14.10.2. Retail Pharmacies
14.10.3. Online Pharmacies
14.11. Market Attractiveness, by Distribution Channel
14.12. Market Value Forecast, by Country/Sub-region, 2020-2034
14.12.1. China
14.12.2. Japan
14.12.3. India
14.12.4. Australia & New Zealand
14.12.5. Rest of Asia Pacific
14.13. Market Attractiveness Analysis
14.13.1. By Drug Class
14.13.2. By Disease Indication
14.13.3. By Type
14.13.4. By Route of Administration
14.13.5. By Distribution Channel
14.13.6. By Country/Sub-region
15. Latin America Gastroparesis Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2020-2034
15.2.1. Prokinetic Agents
15.2.2. Antiemetic Drugs
15.2.3. Proton Pump Inhibitors
15.2.4. Others (Botulinum Toxin Injections, etc.)
15.3. Market Attractiveness, by Drug Class
15.4. Market Value Forecast, by Disease Indication, 2020-2034
15.4.1. Diabetes Gastroparesis
15.4.2. Idiopathic Gastroparesis
15.4.3. Post-surgical Gastroparesis
15.5. Market Attractiveness, by Disease Indication
15.6. Market Value Forecast, By Type, 2020-2034
15.6.1. Over-the-Counter Drugs
15.6.2. Prescription Drugs
15.7. Market Attractiveness, By Type
15.8. Market Value Forecast, by Route of Administration, 2020-2034
15.8.1. Oral
15.8.2. Injectables
15.8.3. Nasal
15.9. Market Attractiveness, by Route of Administration
15.10. Market Value Forecast, by Distribution Channel, 2020-2034
15.10.1. Hospital Pharmacies
15.10.2. Retail Pharmacies
15.10.3. Online Pharmacies
15.11. Market Attractiveness, by Distribution Channel
15.12. Market Value Forecast, by Country/Sub-region, 2020-2034
15.12.1. Brazil
15.12.2. Mexico
15.12.3. Rest of Latin America
15.13. Market Attractiveness Analysis
15.13.1. By Drug Class
15.13.2. By Disease Indication
15.13.3. By Type
15.13.4. By Route of Administration
15.13.5. By Distribution Channel
15.13.6. By Country/Sub-region
16. Middle East & Africa Gastroparesis Treatment Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Drug Class, 2020-2034
16.2.1. Prokinetic Agents
16.2.2. Antiemetic Drugs
16.2.3. Proton Pump Inhibitors
16.2.4. Others (Botulinum Toxin Injections, etc.)
16.3. Market Attractiveness, by Drug Class
16.4. Market Value Forecast, by Disease Indication, 2020-2034
16.4.1. Diabetes Gastroparesis
16.4.2. Idiopathic Gastroparesis
16.4.3. Post-surgical Gastroparesis
16.5. Market Attractiveness, by Disease Indication
16.6. Market Value Forecast, By Type, 2020-2034
16.6.1. Over-the-Counter Drugs
16.6.2. Prescription Drugs
16.7. Market Attractiveness, By Type
16.8. Market Value Forecast, by Route of Administration, 2020-2034
16.8.1. Oral
16.8.2. Injectables
16.8.3. Nasal
16.9. Market Attractiveness, by Route of Administration
16.10. Market Value Forecast, by Distribution Channel, 2020-2034
16.10.1. Hospital Pharmacies
16.10.2. Retail Pharmacies
16.10.3. Online Pharmacies
16.11. Market Attractiveness, by Distribution Channel
16.12. Market Value Forecast, by Country/Sub-region, 2020-2034
16.12.1. GCC Countries
16.12.2. South Africa
16.12.3. Rest of Middle East & Africa
16.13. Market Attractiveness Analysis
16.13.1. By Drug Class
16.13.2. By Disease Indication
16.13.3. By Type
16.13.4. By Route of Administration
16.13.5. By Distribution Channel
16.13.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix (By Tier and Size of Companies)
17.2. Market Share Analysis, by Company (2023)
17.3. Company Profiles
17.3.1. Abbott Laboratories
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. AbbVie Inc.
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. AstraZeneca plc
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. Bayer AG
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. Cipla Limited
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. Evoke Pharma
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. Pfizer Inc.
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. Salix Pharmaceuticals, Inc.
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. The Takeda Pharmaceutical Company Limited
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
17.3.10. Teva Pharmaceutical Industries Ltd.
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. Financial Overview
17.3.10.4. SWOT Analysis
17.3.10.5. Strategic Overview